Meet With the Key Influencers Shaping Paragraph IV Litigation this April

Share

As the industry prepares to address the fall out of global pharmaceutical patent losses of billions of dollars on the Hatch-Waxman landscape, ACI’s Annual Paragraph IV Disputes Conference has never been more relevant. Coming back to New York for its 14th iteration, Paragraph IV Disputes will take place on April 27-28 at the Conrad Hotel.

Each spring, leading pharmaceutical patent litigators for brand name and generic drug companies gather at the Paragraph IV Disputes conference to discuss, debate, and analyze the latest trends, judicial rulings and legislative developments affecting Hatch-Waxman litigation.

The 2020 Agenda Features:

FIRESIDE CHAT WITH THE FEDERAL CIRCUIT
Exclusive interview with the Hon. Kathleen M. O’Malley, United States Circuit Judge

DISTRICT COURT INSIGHTS
Interactive discussions with District Court Judges and Magistrate Judges from D.N.J.; D. Del.; E.D. Pa.; E.D. Tex.

SPECIAL FOCUS SESSIONS ON THE PTAB
APJs Roundtable and advanced discussions on policy, practice, procedure, and the Appointments Clause

FTC KEYNOTE ADDRESS
Insights on antitrust developments impacting brands and generics

FDA THINK TANK
Now Confirmed: Representatives from United States Food and Drug Administration

  • Grail Sipes, Deputy Center Director for Regulatory Policy, CDER
  • Maryll Toufanian, Director, FDA Office of Generic Drug Policy, CDER

FOUR NEW BREAKOUT TRACKS
Featuring an In-House Solutions Studio and Litigators War Room

EXTENDED NETWORKING BREAKS
Connect and reconnect with industry colleagues and establish new relationships

Last year’s event sold out so it is strongly encouraged that you reserve your seat soon.

Share

Warning & Disclaimer: The pages, articles and comments on IPWatchdog.com do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author as of the time of publication and should not be attributed to the author’s employer, clients or the sponsors of IPWatchdog.com. Read more.